- Apyx Medical Corp APYX announced results from Phase 2 of its Investigational Device Exemption (IDE) study of the Renuvion device to improve the appearance of lax skin in the neck and submental region.
- The 65-subject study showed that the primary effectiveness endpoint of the study was met, with 82.5% of subjects demonstrating improvement in the appearance of lax skin at six months post-procedure.
- Related: Why Apyx Medical Shares Are Trading Higher Today?
- 96.9% of subjects experienced no to moderate pain during the first seven days following the procedure.
- Additional effectiveness endpoints in the study also demonstrated success, with 85.5% of subjects rating themselves as improved and 87.1% of subjects rated improved by the study investigators at the 6-month follow-up visit.
- No serious adverse events were reported in the study related to the Renuvion device or the study procedure.
- Price Action: APYX shares closed 5.16% higher at $6.93 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in